Analysis of Intas's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
FEATURES AND BENEFITS
Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.
Having entered the biosimilars market in 2004, Intas currently markets four biosimilar products in India and other semi-regulated markets of Africa, Asia Pacific, and Latin America.
The company has had an active strategy of expansion overseas, but has now shifted to focus on targeting the domestic market due to lower than expected returns from biosimilars and the requirement for high levels of investment in order to penetrate major markets.
YOUR KEY QUESTIONS ANSWERED
See where Intas's portfolio of four marketed biosimilar products fit in to its wider strategy
Assess the prospects for Intas's biosimilars pipeline, which includes the monoclonal antibody rituximab in Phase III development in India
Table of Contents
Table of Contents
ABOUT THIS REPORT
Definition of biosimilars and copy biologics
PharmaVitae Explorer database
Intas biosimilars overview
Intas biosimilars infrastructure
Intas biosimilars SWOT analysis
Biosimilars account for only a small part of Intas's business
Synergies with oncology generics and plasma protein products
Return to focus on the domestic market
Biosimilars face intense competition in India
Intas's biosimilar portfolio
Epofit/Erykine (epoetin alfa)
Neukine and Neupeg (filgrastim and pegfilgrastim)
Intalfa (interferon alfa-2b)
Interferon alfa market size
Intas Medi Devices
Deals and alliances
Table: Intas biosimilars development and marketing capabilities
Table: Intas's biosimilar brands price comparison with reference brands, 2012
Table: Intas's biosimilar/copy-biologic portfolio
Table: Sales of key epoetin brands in the seven major markets ($m), 2011-16
Table: Pipeline and marketed biosimilar/copy-biologic epoetin drugs, 2012
Table: Sales of key filgrastim and pegfilgrastim brands in the seven major markets ($m), 2011-16
Table: Pipeline and marketed biosimilar/copy-biologic filgrastim and pegfilgrastim drugs
Table: Sales of key interferon alfa brands in the seven major markets ($m), 2011-16
Table: Pipeline and marketed biosimilar/copy-biologic interferon alfa drugs
Table: Intas deal activity and biosimilar deals, 2010-12
Table: Exchange rates, 2012
Figure: The PharmaVitae Explorer
Figure: Intas biosimilars overview
Figure: Intas SWOT analysis
Figure: Proportion of government and private health expenditure versus personal disposable income in India and other major markets, 2009
Figure: Intas total company revenues showing share attributed to biopharmaceuticals, 2005-11
Figure: Synergies provided by overlap within Intas Biopharmaceuticals
Figure: Intas Pharmaceuticals sales, by geography, FY2008-10